-transparent.png){kind=logo}
Starvation is well known to induce immune suppression. Moreover, the concentration of 2-B4O, an endogenous sugar acid, is elevated in the circulation during starvation. To determine if these events are related, the influence of 2-B4O on experimental allergic encephalomyelitis (EAE) in Lewis rats, a model of human multiple sclerosis (MS), was studied. EAE, characterized by paralysis of hind legs, was induced by immunization with residues 68 to 84 (MB 68-84) of the guinea pig myelin basic protein (MBP) in complete adjuvant H37Ra. Interestingly, the daily administration of 2-B4O intraperitoneally from the day of MB 68-84 immunization (day 0) to day 20 dramatically suppressed the clinical severity of EAE. The daily administration of 2-B4O intraperitoneally from day 0 to day 7 also markedly reduced the clinical symptoms of EAE. In fact, passively induced EAE, using Con A activated spleen cells from rats immunized with MB 68-84 in H37Ra, was also inhibited by daily administration of 2-B4O. Histological examination confirmed clinical findings and revealed that mononuclear cell infiltration into the central nervous system was significantly inhibited by 2-B4O. To clarify the mechanism(s) responsible for suppression of EAE, the effects of 2-B4O on the immune responses to MB 68-84 were examined. When rats were treated daily with 2-B4O for 15 days after immunization with MB 68-84 in H37Ra, the delayed-type hypersensitivity (DTH) response to MB 68-84 was significantly reduced in 2-B4O treated rats as compared with saline treated rats. The proliferative response to MB 68-84 of spleen cells from 2-B4O treated rats was also significantly lower than that of saline treated rats. Our data demonstrate that 2-B4O has the potential to suppress autoimmune responses in both inductive and effector phases. 2-B4O may have significant potential to treat autoimmune diseases.
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
September 2010,
Physiology & behavior,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
November 2003,
Experimental biology and medicine (Maywood, N.J.),
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
December 2000,
Clinical and experimental immunology,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
September 1971,
Neurosciences Research Program bulletin,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
March 1985,
Journal of immunology (Baltimore, Md. : 1950),
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
October 1999,
Clinical and experimental immunology,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
January 1987,
Journal of neuroscience research,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
January 1986,
No to shinkei = Brain and nerve,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
August 1982,
Clinical and experimental immunology,
M Naiki, and
Y Takeoka, and
H Yago, and
Y Kurimoto, and
M E Gershwin, and
S Suehiro
February 2003,
Immunopharmacology and immunotoxicology,
